Orion’s Darolutamide Achieves 1EP in P-III ARAMIS study in Men with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

 Orion’s Darolutamide Achieves 1EP in P-III ARAMIS study in Men with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

Orion’s Darolutamide Achieves 1EP in P-III ARAMIS study in Men with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

Shots:

  • The P-III ARAMIS study involves assessing of Darolutamide (600mg bid) PO vs PBO in 1500 patients in ratio (2:1) with nmCRPC who are currently being treated with ADT
  • The (Androgen Receptor inhibiting Agent for MetastatIc-free Survival) study demonstrated MFS as 1EP & OS as 2EP and showed consistency with previous results in safety, efficacy and tolerability
  • Darolutamide PO is an androgen receptor (AR) antagonist, jointly developed by Bayer & Orion and also received FTD from the US. Bayer plans to file its MAA on the basis of above results 

Click here to read full press release/ article | Ref: Bayer | Image: 20minutos

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post